0
Deep & Emerging Tech·September 10, 2026·1 min read

Seattle biotech BrainChild Bio raises $116M to advance CAR T therapy for childhood brain cancer

Share

$116M into CAR T for DIPG shows capital flowing into ultra-hard, small-population indications where platform tech can later expand. If you’re in biotech, this is another data point that deep, modality-specific expertise plus a clear expansion path is fundable even when the first market is narrow and brutal.